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Background: Mild cognitive deficits, mainly in frontal-executive function and memory, have been
reported in patients with essential tremor (ET). Furthermore, an association between ET and de-
mentia has been reported in a single population-based study in Spain. This has not been confirmed
elsewhere.
Objective: To determine whether baseline ET is associated with prevalent and incident dementia
in an ethnically diverse, community-based sample of elders.
Methods:Community-dwelling elders in northernManhattan were enrolled in a prospective cohort
study. Baseline ET diagnoses were assigned from handwriting samples. Dementia was diagnosed
at baseline and follow-up using DSM-III-R criteria.
Results: In cross-sectional analyses, 31/124 (25.0%) ET cases had prevalent dementia vs 198/
2,161 (9.2%) controls (odds ratio [OR]unadjusted ! 3.31, 95% confidence interval [CI] ! 2.15–
5.09, p " 0.001; ORadjusted ! 1.84, 95% CI ! 1.13–2.98, p ! 0.01). In prospective analyses,
17/93 (18.3%) ET cases vs 171/1,963 (8.7%) controls developed incident dementia (hazard
ratio [HR]unadjusted ! 2.78, 95% CI ! 1.69–4.57, p " 0.001; HRadjusted ! 1.64, 95% CI !
0.99–2.72, p! 0.055).
Conclusions: In a second population-based study of elders, essential tremor (ET) was associated
with both increased odds of prevalent dementia and increased risk of incident dementia. Presence
of dementia, therefore, appeared to be greater than that expected for age (i.e., a disease-
associated feature). Rather than attributing cognitive complaints in patients with ET to old age,
assessment and possible treatment of dementia should be routinely incorporated into the treat-
ment plan. Neurology® 2009;73:621–625
GLOSSARY
AD ! Alzheimer disease; CES-D ! Center for Epidemiologic Studies–Depression; CI ! confidence interval; DSM-IV ! Diag-
nostic and Statistical Manual ofMental Disorders,4th edition;ET! essential tremor;HR! hazard ratio;MCI!mild cognitive
impairment;MCI!M!MCI with memory impairment;MCI-M!MCI without memory impairment;OR! odds ratio;UPDRS!
Unified Parkinson’s Disease Rating Scale;WHICAP!Washington/Hamilton Heights and Inwood Aging Project.
Essential tremor (ET), a progressive neurologic disease, is among the most prevalent movement
disorders.1,2 In addition to action tremor and other motor features, recent studies report non-
motor features.3-5 In a growing number of studies, mild cognitive problems are being observed
in ET cases.6-8 Furthermore, an association between ET and dementia was reported in a recent
population-based study in central Spain.9,10 This novel association has yet to be verified in
other populations. In a large, multiethnic study of elderly persons living in northern Manhat-
tan, NY, we determined whether ET is 1) associated with prevalent dementia and 2) a baseline
risk factor for incident dementia. Our overarching goal was to confirm whether dementia
occurs in ET above and beyond that expected for age (i.e., to determine whether dementia is a
disease-associated feature), which is an issue that has implications for the evaluation and treat-
ment of patients in clinical settings.
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METHODS Study population. Participants (2,776) were
enrolled in the Washington/Hamilton Heights and Inwood Ag-
ing Project (WHICAP) II cohort. These participants, who com-
prise individuals from 3 ethnic categories (white, African
American, Hispanic), were identified from a probability sample
of Medicare beneficiaries (age !65 years) residing in the north-
ern Manhattan communities of Washington Heights and In-
wood. The WHICAP II cohort represents a combination of
continuing members of a cohort recruited between 1992 and
1994 (WHICAP I; n ! 602) and members of a new cohort
recruited between 1999 and 2002 (n! 2,174).11,12
Participants underwent identical baseline and follow-up as-
sessments every 18 months. Handwriting assessments were at
baseline.
Standard protocol approvals, registrations, and patient
consents. Study procedures and recruitment were approved by
the Columbia University Internal Review Board and written,
informed consent was obtained from all participants.
In-person evaluation. A trained research assistant adminis-
tered an in-person structured health interview (demographics,
medical history, medications). The 10-item Center for Epide-
miologic Studies–Depression (CES-D) scale assessed depres-
sive symptoms; as done previously, scores !4 were coded as
depressed.13,14
General medical doctors administered a neurologic examina-
tion, including a 10-item version of the motor Unified Parkin-
son’s Disease Rating Scale (UPDRS).15 These doctors were
trained using a structured protocol.15 Interrater reliability was
substantial to excellent and percent concordance with a move-
ment disorder neurologist’s ratings was high.15
A neuropsychological battery, conducted by a trained tester,
included measures of abstract reasoning, learning and memory,
language, visuospatial ability, and orientation.15-17
Participants also generated several handwriting samples. The
first sample, collected during neuropsychological testing, was a series
of 5 shapes (e.g., triangle, diamond) that were copied.18 The second
sample was a trail making test.19 As documented,20 a medical student
(S.T.) was trained by a senior movement disorder neurologist
(E.D.L.) to rate the severity of tremor in these 6 items; interrater
agreement was high (intraclass correlation coefficient ! 0.80).
These ratings (examples in figure 1 in reference 20) were blinded to
demographic, clinical, and neuropsychological data and dementia
diagnoses. Ratings were 0 (no tremor), 0.5 (possible tremor), 1.0
(clear tremor that was mild, equivalent to a rating of 2 on an
Archimedes spiral in the rating scale of Bain and Findley21), 1.5
(mild to moderate tremor, equivalent to a rating21 of 3–4), or 2
(moderate or greater tremor, equivalent to a rating21!5). Based on
the 6 rated items, a total tremor score was generated (range !
0–12).
Diagnoses. The method of diagnosing ET, documented in de-
tail,20 was based on published data on observed differences in sever-
ity of tremor in ET cases vs normal controls.21 Bain and Findley21
indicated that their tremor rating!2may be used to distinguish ET
from enhanced physiologic tremor because this rating corresponded
with twice that of the 95th percentile seen in healthy controls. Their
rating of 2 is equal to our rating of 1.0. A tremor rating of 1.0 on
each of our 6 rated items would result in a total tremor score of 6.0.
To bemore inclusive (accounting for the possibility that 1 of 6 items
could have received a rating of 0.5), we considered those with total
tremor scores !5.5 as having preliminary diagnoses of ET. The
senior neurologist reviewed the records of all participants with pre-
liminary ET diagnoses, and independently re-rated tremor, assign-
ing a total tremor score. Also, as an additional test, a handwritten
sentence, which was completed by participants, was rated (E.D.L.)
A final ET diagnosis was conservatively assigned to participants
when the senior neurologist confirmed a total tremor score!5.5 or
rated the handwritten sentence !2 (moderate or greater tremor,
equivalent to a rating!5 in Bain and Findley21) (example in figure
2 in reference 20). These final ET diagnoses were blinded to all
clinical data. Patients with PD by history or neurologic examination
or with tremor related to medications, hyperthyroidism, or another
neurologic disorder were not assigned final ET diagnoses. Subse-
quently, 9 ET cases were randomly selected for enrollment in an
epidemiologic study22; each had a complete videotaped tremor ex-
amination (arm extension, pouring, drinking, using spoon, finger-
nose-finger, writing); the ET diagnosis was confirmed using
published research criteria22 in 100% of these.
The general medical doctors assigned a preliminary diagnosis
of PD if a participant 1) had !2 cardinal signs of parkinsonism
on neurologic examination, 2) was told previously that he or she
had a diagnosis of PD, or 3) had ever used levodopa.15 PD diag-
noses were confirmed by a WHICAP study neurologist based on
a second, more detailed neurologic examination.
Dementia diagnoses, assigned by consensus conference of
neurologists and neuropsychologists, were based on a neuropsy-
chological battery and the physician-administered neurologic ex-
amination, blinded to tremor ratings.23 Participants were
considered demented if, based on neuropsychological testing,
they demonstrated impairment in memory and at least 2 other
cognitive domains, in the absence of delirium.15,23 Criteria for
dementia from the DSM-III-R were applied in addition to ancil-
lary information from medical charts and laboratory studies in
the final evaluation.24 Evidence of deficits in social or occupa-
tional functioning was also required for the consensus diagnosis.
This information was also used to determine the type and etiol-
ogy of dementia. Diagnosis of probable or possible Alzheimer
disease (AD) was based on National Institute of Neurological
and Communicative Disorders and Stroke–Alzheimer’s Disease
and Related Disorders Association criteria.25
Based on the neuropsychological test battery, participants
were assigned diagnoses of mild cognitive impairment (MCI)
according to published criteria.16,17,26,27 MCI was stratified into
MCI with memory impairment (MCI#M) and MCI without
memory impairment (MCI-M).15
Baseline study sample. The baseline sample included 2,776
participants (mean age 78.2$ 7.1 years, mean education 9.9$ 4.9
years).We excluded 491 participants who had 1) refused the writing
tasks due to poor eyesight or difficulty following the instructions
(n! 381) (none refused these tasks due to tremor); 2) incomplete
neuropsychological tests (n! 62); or 3) preliminary or confirmed
diagnoses of PD (n! 48 of 2,776! 1.7%). The remaining 2,285
(82.3% of 2,776) participants were similar to the initial 2,776 in
gender (1,553 [68.0%] vs 1,889 [68.0%] women, p ! 0.93), eth-
nicity (874 [38.2%] vs 1,099 [39.6%] Hispanic, p ! 0.34), and
education (10.1$ 4.8 vs 9.9$ 4.9 years, p! 0.15). The remaining
2,285 were 0.6 years younger than the initial 2,776 (77.6$ 6.9 vs
78.2$ 7.1 years, p! 0.002).
Analyses. Analyses, performed in SPSS version 11.0, included
"2 and t tests and analysis of variance.
In cross-sectional analyses, logistic regression analyses tested
the association of the outcome variable with the independent
variable (ET vs control). In different models, outcome variables
were 1) demented vs nondemented (nondemented included
MCI categories and no cognitive impairment), 2) MCI#M vs
no cognitive impairment (excluding demented and MCI-M),
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and MCI-M vs no cognitive impairment (excluding demented
and MCI#M).
In prospective analyses, Cox proportional hazards regression,
which yielded hazard ratios (HRs), compared the risk of develop-
ing incident dementia (or incident MCI) in participants with vs
without baseline ET. The time-to-event variable was time from
baseline examination to diagnosis of dementia or MCI.
In adjusted models, we included variables that were associ-
ated with both ET and dementia (or MCI) (p " 0.05) or for
which a priori evidence was considerable that the variable may be
a confounder. Variables considered included age (years), gender,
ethnicity, education (years), depression, APOE #4 status, and
self-reported medical illnesses (hypertension, congestive heart
failure, stroke, diabetes, arthritis, peripheral vascular disease).
We also considered a cohort variable (1992–1994 vs 1999–
2002). A complete inventory of all current medications (includ-
ing tremor-exacerbating medications) was available, and
medication variables were added as covariates (taking each med-
ication vs not) in an adjusted model.
RESULTS Cross-sectional analyses (baseline data).
There were 124 (5.4% of 2,285) prevalent ET cases
and 2,161 controls. ET cases were older than con-
trols (80.9 $ 7.5 vs 77.4 $ 6.8 years, p " 0.001),
had fewer years of education (8.2 $ 4.8 vs 10.2 $
4.7 years, p" 0.001), and fewer were white (21/124
[16.9%] vs 625/2,161 [28.9%], p ! 0.01). APOE
#4 gene status did not differ (table e-1 on theNeurol-
ogy® Web site at www.neurology.org).
There were 229 (10.0% of 2,285) participants
with prevalent dementia and 452 (19.8% of 2,285)
with prevalent MCI (235 MCI#M, 217 MCI-M)
(table e-2). Participants with prevalent dementia
were older than participants with no cognitive im-
pairment, had fewer years of education, and fewer
were white. Also, a larger proportion had depression
(CES-D !4), hypertension, congestive heart failure,
stroke, and positive APOE #4 gene status (table e-2).
Thirty-one (25.0%) of 124 ET cases had preva-
lent dementia vs 198 (9.2%) of 2,161 controls. ET
was associated with prevalent dementia in unad-
justed models (odds ratio [OR] ! 3.31, 95% confi-
dence interval [CI] ! 2.15–5.09, p " 0.01) and
adjusted models (OR adjusted for age [years], educa-
tion [years], and ethnicity ! 1.84, 95% CI ! 1.13–
2.98, p ! 0.01). Participants with dementia were
stratified by etiology; 29 of 31 [93.5%] ET cases
with dementia had AD and 179 of 198 [90.4%] con-
trols with dementia had AD ("2 ! 0.32, p ! 0.57).
We conducted several secondary analyses. First,
we excluded 452 participants with MCI; adjusted
(age, education, ethnicity) OR ! 1.84, 95% CI !
1.11–3.06, p ! 0.02. Second, we excluded 462 par-
ticipants with depression (CES-D score !4); ad-
justed OR! 2.10, 95% CI! 1.20–3.68, p! 0.01.
Third, each medication variable (including tremor-
exacerbating medications) was added as a covariate;
adjusted (age, education, ethnicity, each medication)
OR ! 1.97, 95% CI ! 1.08–3.58, p ! 0.03.
Fourth, we considered cohort as a covariate; adjusted
(age, education, ethnicity, cohort) OR ! 1.82, 95%
CI! 1.12–2.95, p! 0.02. Finally, participants were
stratified by APOE #4 gene status: adjusted (age, ed-
ucation, and ethnicity) ORAPOE å4 gene positive !
1.82, 95% CI ! 0.72–4.59, p ! 0.20, and adjusted
ORAPOE å4 gene negative ! 1.48, 95% CI ! 0.72–
3.04, p ! 0.29.
Eleven (8.9%) ET cases had MCI#M and 15
(12.1%) had MCI-M vs 224 (10.4%) and 202 (9.3%)
in controls. ET was not associated with MCI#M (un-
adjusted OR! 1.13, 95%CI! 0.59–2.16, p! 0.72;
adjusted OR! 1.08, 95%CI! 0.56–2.10, p! 0.81)
or MCI-M (unadjusted OR! 1.70, 95% CI! 0.96–
3.04, p! 0.07; adjusted OR! 1.47, 95%CI! 0.81–
2.66, p! 0.20).
Prospective analyses. We excluded 229 participants
with baseline dementia, leaving 2,056 participants
(93 ET cases, 1,963 controls). Mean follow-up
was 3.8 $ 2.2 years. Seventeen (18.3%) of 93 ET
cases developed dementia vs 171 (8.7%) of 1,963
controls. ET was associated with risk of incident de-
mentia in unadjusted (HR! 2.78, 95% CI! 1.69–
4.57, p " 0.001) and adjusted models (HR adjusted
for age, education, ethnicity ! 1.64, 95% CI !
0.99–2.72, p ! 0.055). All participants with inci-
dent dementia had AD.
In secondary analyses, we excluded 316 partici-
pants with incident MCI; adjusted (age, education,
ethnicity) HR ! 2.07, 95% CI ! 1.18–3.66, p !
0.01. Second, we excluded 388 participants with de-
pression; adjusted HR ! 1.76, 95% CI ! 1.01–
3.07, p ! 0.048. Third, each medication variable
was added as a covariate; adjusted (age, education,
ethnicity, each medication) HR ! 1.71, 95% CI !
0.97–3.01, p ! 0.06. Fourth, adjusting for cohort,
adjusted (age, education, ethnicity, cohort) HR ! 1.61,
95% CI ! 0.97–2.67, p ! 0.07. Finally, we at-
tempted to stratify by APOE #4 gene status, but
there were only 2 APOE #4 positive ET cases with
dementia. In these analyses, adjusted (age, education,
and ethnicity) HRAPOE å4 gene positive ! 0.40, 95%
CI ! 0.09–1.71, p ! 0.22 and adjusted
HRAPOE å4 gene negative ! 1.89, 95% CI ! 0.97–
3.65, p ! 0.06. Finally, 4 cases and no controls de-
veloped incident PD during follow-up (ET # PD);
after excluding these 4, adjusted HR ! 1.64, 95%
CI ! 0.00–2.71, p ! 0.056.
We excluded 452 participants with baseline MCI.
In these prospective analyses, 1 (1.5%) ET case devel-
oped incident MCI#M and 7 (10.4%) developed inci-
dent MCI-M; 156 (10.1%) controls developed
MCI-M and 152 (9.9%) controls developed MCI-M.
ET was not associated with increased risk of incident
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MCI#M (unadjusted HR ! 0.18, 95% CI ! 0.03–
1.31, p! 0.09; HR adjusted for age, education, ethnic-
ity ! 0.14, 95% CI ! 0.02–1.00, p ! 0.05) or
MCI-M (unadjusted HR ! 1.33, CI ! 0.62–2.84,
p! 0.46; HR adjusted for age, education, ethnicity!
0.97, 95% CI! 0.45–2.09, p! 0.94).
DISCUSSION In a population-based sample of el-
derly, ET was associated in adjusted analyses with a
near-doubling of the odds of prevalent dementia and an
approximately 60% increased risk of incident dementia.
ET is a progressive neurologic disease whose preva-
lence is particularly high among elders, and which con-
tinues to rise with advancing age; in the oldest old, the
prevalence has been reported to be as high as 21.7%.20
A variety of non-motor features, including cognitive
and psychiatric, are now appreciated and undergoing
further scientific scrutiny in case-control studies. While
mild problems in cognition in excess of aging have been
reported in many case-control studies,6-8 there have
been few attempts to examine whether these cognitive
problems are more considerable.
One prior population-based study in central Spain
reported an association between ET and prevalent de-
mentia; their adjustedOR, 1.70, is similar to that which
we report in New York.10 In that study, the association
was limited to older onset ET and dementia. We did
not collect data on age at onset of ET so we were not
able to determine whether the association was more ro-
bust in older onset cases. When taken together, these 2
studies, in different populations, suggest that ET, like
PD, is a neurologic disorder associated with increased
odds of dementia. In PD, however, the reported ORs
are higher (e.g., 3.75)28 than those reported in ET. An
incidence study from the same cohort in central Spain
reported an association between ET and incident de-
mentia (adjusted HR of 1.66).9 These results are strik-
ingly similar to the HRs reported here (1.64) in a
second population.
Both this and the Spanish study were population-
based. Patients in clinical settings (especially movement
disorder practices) are probably self-selected not to have
dementia, thereby minimizing any apparent association
between ET and dementia in those samples. This is be-
cause patients with dementia are more likely to attend
memory disorders clinics. Also, onset of dementia may
make attendance at a movement disorders clinic more
difficult, especially if the motivation for attending that
clinic is marginal (e.g., longstanding tremor that re-
sponds poorly to medication).
We excluded 1.7% of participants who either were
diagnosed with PD (in the present study or in the past)
or had ever used levodopa. Indeed, this prevalence of
PD or possible PD (1.7%) is slightly in excess of that in
other elderly population-based samples (approximately
1%).29 Therefore, it is unlikely that our participants
with ET actually had PD (i.e., diagnostic misclassifica-
tion by underdiagnosis of PD).
As in our published prevalence study,20 ET was
diagnosed based on handwriting. This approach to
distinguishing ET tremor from normal tremor has
been advocated by other researchers as well.21 Yet it is
conceivable that there was some diagnostic misclassi-
fication. However, this would have biased our results
toward the null hypothesis, making it more difficult
to detect an association between ET and dementia.
We further evaluated the validity our ET diagnoses
in a small random subsample of cases, demonstrating
complete (100%) agreement. Further indicating that
the diagnostic method was valid is that our preva-
lence estimate, 5.5%,20 based on this method, falls
well within the range of other population-based stud-
ies that used different diagnostic methods.
The mechanistic basis for this association is unclear.
Recent postmortem studies have demonstrated an in-
creased prevalence of brainstem Lewy bodies in ET,30,31
raising the question as to whether ET cases with demen-
tia have Lewy body pathology. Alternatively, other
pathologic mechanisms (e.g., cerebrovascular, Alzheimer-
type changes) could better explain this association.
Imaging and postmortem studies have yet to com-
pare the prevalence of subcortical vascular pathology
in ET cases and controls. In the Spanish study, the
majority of ET cases with dementia had clinical diag-
noses of AD9; we report similar findings here. Inter-
estingly, a recent postmortem study found slightly
more Alzheimer-type plaque and tangle pathology in
ET cases than age-matched controls.32,33 Clearly, the
mechanistic basis for the dementia in ET merits ad-
ditional study. Furthermore, a longer follow-up of
our cohort would provide additional information
about the possible subsequent development of other
neurodegenerative disorders.
It is unclear why neither we nor the Spanish study
found an association between ET and MCI. Partici-
pants with MCI represent a mixed group, some of
whom eventually convert to dementia yet others do not.
Our analyses were limited to the elderly. ET may
occur in younger patients; it would be advantageous
to examine if this association is also found in a
younger sample.
This and the Spanish study have clinical implica-
tions. Prevalence of dementia in ET appears to be
greater than expected for age, indicating that dementia
is likely to be a disease-associated feature of ET rather
than a mere consequence of aging. This suggests that
cognitive issues and dementia should more formally en-
ter the clinical dialogue in ET rather than being re-
garded as normal features of aging. The implication of
these findings, in terms of the routine clinical assess-
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ment of cognitive impairment in patients with ET, re-
quires further consideration. Furthermore, possible
treatment of dementia should be considered.
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